ID   SU-DIPG-IV
AC   CVCL_IT39
AS   CVCL_IP14
SY   SUDIPGIV; SU-DIPG-4; SUDIPG4; DIPG IV; DIPGIV; DIPG 4; DIPG-4; DIPG4; SJHGG054832
DR   BTO; BTO_0005955
DR   cancercelllines; CVCL_IT39
DR   GEO; GSM4969586
DR   GEO; GSM4969587
DR   GEO; GSM4969588
DR   GEO; GSM4969589
DR   GEO; GSM4969615
DR   GEO; GSM4969637
DR   GEO; GSM4969638
DR   GEO; GSM4969639
DR   Wikidata; Q54970734
RX   PubMed=25366336;
RX   PubMed=25939062;
RX   PubMed=28823557;
RX   PubMed=31439867;
RX   PubMed=33319914;
RX   PubMed=34078608;
RX   PubMed=34215733;
CC   Doubling time: 3.0 days (PubMed=34215733).
CC   Sequence variation: Mutation; HGNC; HGNC:171; ACVR1; Simple; p.Gly328Val (c.983G>T); ClinVar=VCV000376363; Zygosity=Unspecified (PubMed=28823557).
CC   Sequence variation: Mutation; HGNC; HGNC:4776; H3C2; Simple; p.Lys28Met (c.83A>T) (H3.1K27M); Zygosity=Unspecified (PubMed=25939062).
CC   Omics: Genomics; ChIP-seq; H3K27ac.
CC   Omics: Genomics; ChIP-seq; H3K27me3.
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: In situ; Brainstem, pons; UBERON=UBERON_0000988.
ST   Source(s): PubMed=25939062; PubMed=28823557
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 7,12
ST   D16S539: 9,12
ST   D21S11: 29,31
ST   D5S818: 12,13
ST   D7S820: 10,11
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 15,19
DI   NCIt; C94764; Diffuse intrinsic pontine glioma
DI   ORDO; Orphanet_497188; Diffuse intrinsic pontine glioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   2-3Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 10-04-25; Version: 12
//
RX   PubMed=25366336; DOI=10.1093/neuonc/nou303; PMCID=PMC4482855;
RA   Green A.L., Ramkissoon S.H., McCauley D., Jones K., Perry J.A.,
RA   Hsu J.H.-R., Ramkissoon L.A., Maire C.L., Hubbell-Engler B., Knoff D.S.,
RA   Shacham S., Ligon K.L., Kung A.L.-J.;
RT   "Preclinical antitumor efficacy of selective exportin 1 inhibitors in
RT   glioblastoma.";
RL   Neuro-oncol. 17:697-707(2015).
//
RX   PubMed=25939062; DOI=10.1038/nm.3855; PMCID=PMC4862411;
RA   Grasso C.S., Tang Y.-J., Truffaux N., Berlow N.E., Liu L.-N.,
RA   Debily M.-A., Quist M.J., Davis L.E., Huang E.C., Woo P.J.,
RA   Ponnuswami A., Chen S., Johung T.B., Sun W.-C., Kogiso M., Du Y.-C.,
RA   Qi L., Huang Y.-L., Hutt-Cabezas M., Warren K.E., Le Dret L.,
RA   Meltzer P.S., Mao H., Quezado M., van Vuurden D.G., Abraham J.,
RA   Fouladi M., Svalina M.N., Wang N., Hawkins C., Nazarian J.,
RA   Alonso M.M., Raabe E.H., Hulleman E., Spellman P.T., Li X.-N.,
RA   Keller C., Pal R., Grill J., Monje M.;
RT   "Functionally defined therapeutic targets in diffuse intrinsic pontine
RT   glioma.";
RL   Nat. Med. 21:555-559(2015).
//
RX   PubMed=28823557; DOI=10.1016/j.cell.2017.07.016; PMCID=PMC5587159;
RA   Qin E.Y., Cooper D.D., Abbott K.L., Lennon J., Nagaraja S., Mackay A.,
RA   Jones C., Vogel H., Jackson P.K., Monje M.;
RT   "Neural precursor-derived pleiotrophin mediates subventricular zone
RT   invasion by glioma.";
RL   Cell 170:845-859.e19(2017).
//
RX   PubMed=31439867; DOI=10.1038/s41467-019-11732-6; PMCID=PMC6706443;
RA   Fons N.R., Sundaram R.K., Breuer G.A., Peng S., McLean R.L.,
RA   Kalathil A.N., Schmidt M.S., Carvalho D.M., Mackay A., Jones C.,
RA   Carcaboso A.M., Nazarian J., Berens M.E., Brenner C., Bindra R.S.;
RT   "PPM1D mutations silence NAPRT gene expression and confer NAMPT
RT   inhibitor sensitivity in glioma.";
RL   Nat. Commun. 10:3790.1-3790.10(2019).
//
RX   PubMed=33319914; DOI=10.1093/gigascience/giaa136; PMCID=PMC7736793;
RA   Sanders L.M., Cheney A., Seninge L., van den Bout A., Chen M.,
RA   Beale H.C., Kephart E.T., Pfeil J., Learned K., Lyle A.G., Bjork I.,
RA   Haussler D., Salama S.R., Vaske O.M.;
RT   "Identification of a differentiation stall in epithelial mesenchymal
RT   transition in histone H3-mutant diffuse midline glioma.";
RL   GigaScience 9:giaa136.1-giaa136.14(2020).
//
RX   PubMed=34078608; DOI=10.1126/sciadv.abg4126; PMCID=PMC10166578;
RA   Wang J., Huang T.Y.-T., Hou Y., Bartom E.T., Lu X.-Y., Shilatifard A.,
RA   Yue F., Saratsis A.M.;
RT   "Epigenomic landscape and 3D genome structure in pediatric high-grade
RT   glioma.";
RL   Sci. Adv. 7:eabg4126.1-eabg4126.16(2021).
//
RX   PubMed=34215733; DOI=10.1038/s41467-021-24168-8; PMCID=PMC8253809;
RA   He C., Xu K., Zhu X.-Y., Dunphy P.S., Gudenas B., Lin W.-W., Twarog N.,
RA   Hover L.D., Kwon C.-H., Kasper L.H., Zhang J.-Y., Li X.-Y., Dalton J.,
RA   Jonchere B., Mercer K.S., Currier D.G., Caufield W., Wang Y.-Z., Xie J.,
RA   Broniscer A., Wetmore C., Upadhyaya S.A., Qaddoumi I., Klimo P.,
RA   Boop F.A., Gajjar A., Zhang J.-H., Orr B.A., Robinson G.W., Monje M.,
RA   Freeman B.B. 3rd, Roussel M.F., Northcott P.A., Chen T.-S., Rankovic Z.,
RA   Wu G., Chiang J.C.-H., Tinkle C.L., Shelat A.A., Baker S.J.;
RT   "Patient-derived models recapitulate heterogeneity of molecular
RT   signatures and drug response in pediatric high-grade glioma.";
RL   Nat. Commun. 12:4089.1-4089.17(2021).
//